Global Market for Glaucoma Pharmaceuticals to Reach $3.35 Billion by 2015, According to New Report by Global Industry Analysts, Inc.
GIA announces the release of a comprehensive global report on Glaucoma Pharmaceuticals Market. The global glaucoma pharmaceuticals market is projected to exceed $3.35 billion by 2015. Factors driving growth include growing incidence of glaucoma, and increase in aging population.
San Jose, California (PRWEB) February 22, 2010
The US is the leading region for glaucoma pharmaceuticals, wherein glaucoma represents the second leading cause of blindness. Glaucoma is a progressive vision deteriorating disease, afflicting mostly aging individuals over and above the age of 40. Elevated Intraocular Pressure (IOP) (http://www. strategyr. com/Glaucoma_Pharmaceuticals_Market_Report. asp) is a major causative factor for the development of glaucoma. There is no prevention or cure for glaucoma, and medical management of the disease mainly revolves around its control. Vision loss stemming from glaucoma is irreversible and permanent, but medical treatment helps in preventing or slowing down the rate of vision deterioration. If untreated, the disease degenerates and progressively destroys retinal ganglion cells, resulting in a condition medically termed as "optic neuropathy".
The US dominates the world glaucoma pharmaceuticals market as stated by the new market research report on glaucoma pharmaceuticals (http://www. strategyr. com/Glaucoma_Pharmaceuticals_Market_Report. asp). The US glaucoma pharmaceuticals market although trotting along at a healthy pace driven largely by rapidly aging population and emerging trend of combination medications, is however expected to invariably nose-dive with some of the market leading drugs losing patents in the next few years. Among the major drug categories of glaucoma pharmaceuticals, sales in the US are predominantly led by prostaglandin analogues (http://www. strategyr. com/Glaucoma_Pharmaceuticals_Market_Report. asp), followed by Alpha Adrenergic Agonist (http://www. strategyr. com/Glaucoma_Pharmaceuticals_Market_Report. asp), and combination therapies.
Key players profiled in the report include Acadia Pharmaceuticals Inc., Alcon Laboratories Inc., Allergan Inc., Falcon Pharmaceuticals Ltd., Inotek Pharmaceuticals Corp., Inspire Pharmaceuticals Inc., Lexicon Pharmaceuticals Inc., Merck & Co. Inc., NicOx S. A., Novartis International AG, Pfizer Inc., and Santen Pharmaceutical Co. Ltd.
The report titled "Glaucoma Pharmaceuticals: A Global Strategic Business Report" announced by Global Industry Analysts Inc., provides a comprehensive review of glaucoma pharmaceuticals/drug categories, prevalence data, growth drivers, growth inhibitors, research and development, product introductions, product approvals, and recent industry activity. The study provides market analytics for US, and Rest of World. The US market for Glaucoma Pharmaceuticals is further analyzed by different drug classes, which include Alpha Adrenergic Agonist, Beta-Blocker, Carbonic Anhydrase Inhibitor, Combination Therapy, Prostaglandin Analogue, and Others.
For more details about this market research report, please visit - http://www. strategyr. com/Glaucoma_Pharmaceuticals_Market_Report. asp (http://www. strategyr. com/Glaucoma_Pharmaceuticals_Market_Report. asp)
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) (http://www. strategyR. com/) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Email press(at)StrategyR(dot)com
Web Site http://www. StrategyR. com/ (http://www. StrategyR. com/)
###
